Robert L. Wilensky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert L. Wilensky has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Ali Sonel
University of Pennsylvania, University of Pittsburgh, and the Pittsburgh VA Health System, Pittsburgh, PA, USA
1 shared publicationBrett M. Sasseen
From the University of Pennsylvania (B.M.S., R.L.W.), University of Pittsburgh, and the Pittsburgh VA Health System (A.S.), Pittsburgh, Pa, and Indiana University Medical Center, Indianapolis, Ind (N.F., N.B.).
1 shared publicationNaomi Fineberg
From the University of Pennsylvania (B.M.S., R.L.W.), University of Pittsburgh, and the Pittsburgh VA Health System (A.S.), Pittsburgh, Pa, and Indiana University Medical Center, Indianapolis, Ind (N.F., N.B.).
1 shared publicationNils Bang
From the University of Pennsylvania (B.M.S., R.L.W.), University of Pittsburgh, and the Pittsburgh VA Health System (A.S.), Pittsburgh, Pa, and Indiana University Medical Center, Indianapolis, Ind (N.F., N.B.).
1 shared publication
Latest Publications
- 5 September 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (10) , 1107-1113
Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels With Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department With Chest Pain
Background —Although thrombus formation plays a major role in acute coronary syndromes, few studies have evaluated a thrombus marker in risk stratification of patients with chest pain. Furthermore, the relation between markers that reflect myocardial injury and thrombus formation that may predict events in a heterogeneous patient population is unknown. This study correlated markers of thrombus and myocardial injury with early and late ischemic events in consecutive patients with chest pain. Methods and Results —Serum troponin I (TnI), myoglobin, and myosin light chain levels were obtained from 247 patients and urinary fibrinopeptide A (FPA) from 178 of the 247. By multivariate analysis, patients with an elevated FPA level were 4.82 times more likely to die or have myocardial infarction, unstable angina, and coronary revascularization at 1 week ( P =0.002, 95% CI 1.78, 13.03), whereas those with an elevated TnI (>0.2 ng/mL) were 9.41 times more likely ( P P P Conclusions —Elevated FPA and TnI correlated with cardiac events during the initial week in patients presenting to the Emergency Department with chest pain. FPA predicted adverse events and a shorter event-free survival at 6 months.
- 5 September 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (10) , 1107-1113
Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels With Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department With Chest Pain
Background —Although thrombus formation plays a major role in acute coronary syndromes, few studies have evaluated a thrombus marker in risk stratification of patients with chest pain. Furthermore, the relation between markers that reflect myocardial injury and thrombus formation that may predict events in a heterogeneous patient population is unknown. This study correlated markers of thrombus and myocardial injury with early and late ischemic events in consecutive patients with chest pain. Methods and Results —Serum troponin I (TnI), myoglobin, and myosin light chain levels were obtained from 247 patients and urinary fibrinopeptide A (FPA) from 178 of the 247. By multivariate analysis, patients with an elevated FPA level were 4.82 times more likely to die or have myocardial infarction, unstable angina, and coronary revascularization at 1 week ( P =0.002, 95% CI 1.78, 13.03), whereas those with an elevated TnI (>0.2 ng/mL) were 9.41 times more likely ( P P P Conclusions —Elevated FPA and TnI correlated with cardiac events during the initial week in patients presenting to the Emergency Department with chest pain. FPA predicted adverse events and a shorter event-free survival at 6 months.